Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply
Pomara and Imbimbo comment on the study on the use of donanemab in early symptomatic Alzheimer disease. The TRAILBLAZER-ALZ 2 trial 1 provided additional evidence that the APOE4 genotype is a risk factor for amyloid-related imaging abnormalities, especially cerebral edema and effusion. These finding...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2023-12, Vol.330 (23), p.2304 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 23 |
| container_start_page | 2304 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 330 |
| creator | Pomara, Nunzio Imbimbo, Bruno Pietro Evans, Cynthia D Sims, John R |
| description | Pomara and Imbimbo comment on the study on the use of donanemab in early symptomatic Alzheimer disease. The TRAILBLAZER-ALZ 2 trial 1 provided additional evidence that the APOE4 genotype is a risk factor for amyloid-related imaging abnormalities, especially cerebral edema and effusion. These findings are consistent with those from other clinical trials of β-amyloid-targeting monoclonal antibodies in patients with Alzheimer disease. Breakdown of the blood-brain barrier may result in increased drug entry into the central nervous system that could have important safety implications because adverse events are generally dose-dependent. They would be grateful if Dr Sims and colleagues could discuss any data or insights they may have on the possible role of higher CSF donanemab levels in the increased risk for amyloid-related imaging abnormalities associated with the APOE ε4 genotype. |
| doi_str_mv | 10.1001/jama.2023.21106 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2911362861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2911362861</sourcerecordid><originalsourceid>FETCH-proquest_journals_29113628613</originalsourceid><addsrcrecordid>eNqNi7sOgjAYRhujiXiZXZs4A_1bLmUyRjTOXmZSTYmQXpDCgE8vgw_gt5zhnA-hDZAACIGwFloElFAWUACSTJAHMeM-izM-RR4hGffTiEdztHCuJuOApR7a3Z3EtsS5NcJILR64MvgoWjXg66CbzmrRVU-8V5-XrLRscV45KcZPiC-yUcMKzUqhnFz_uETb0_F2OPtNa9-9dF1R2741oypoBsASyhNg_1Vfy40-Ww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2911362861</pqid></control><display><type>article</type><title>Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply</title><source>American Medical Association Journals</source><creator>Pomara, Nunzio ; Imbimbo, Bruno Pietro ; Evans, Cynthia D ; Sims, John R</creator><creatorcontrib>Pomara, Nunzio ; Imbimbo, Bruno Pietro ; Evans, Cynthia D ; Sims, John R</creatorcontrib><description>Pomara and Imbimbo comment on the study on the use of donanemab in early symptomatic Alzheimer disease. The TRAILBLAZER-ALZ 2 trial 1 provided additional evidence that the APOE4 genotype is a risk factor for amyloid-related imaging abnormalities, especially cerebral edema and effusion. These findings are consistent with those from other clinical trials of β-amyloid-targeting monoclonal antibodies in patients with Alzheimer disease. Breakdown of the blood-brain barrier may result in increased drug entry into the central nervous system that could have important safety implications because adverse events are generally dose-dependent. They would be grateful if Dr Sims and colleagues could discuss any data or insights they may have on the possible role of higher CSF donanemab levels in the increased risk for amyloid-related imaging abnormalities associated with the APOE ε4 genotype.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2023.21106</identifier><language>eng</language><publisher>Chicago: American Medical Association</publisher><subject>Abnormalities ; Alzheimer's disease ; Apolipoprotein E ; Blood-brain barrier ; Central nervous system ; Cerebrospinal fluid ; Clinical trials ; Edema ; Effusion ; Genotypes ; Medical imaging ; Monoclonal antibodies ; Neurodegenerative diseases ; Neuroimaging ; Risk factors ; β-Amyloid</subject><ispartof>JAMA : the journal of the American Medical Association, 2023-12, Vol.330 (23), p.2304</ispartof><rights>Copyright American Medical Association Dec 19, 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Pomara, Nunzio</creatorcontrib><creatorcontrib>Imbimbo, Bruno Pietro</creatorcontrib><creatorcontrib>Evans, Cynthia D</creatorcontrib><creatorcontrib>Sims, John R</creatorcontrib><title>Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply</title><title>JAMA : the journal of the American Medical Association</title><description>Pomara and Imbimbo comment on the study on the use of donanemab in early symptomatic Alzheimer disease. The TRAILBLAZER-ALZ 2 trial 1 provided additional evidence that the APOE4 genotype is a risk factor for amyloid-related imaging abnormalities, especially cerebral edema and effusion. These findings are consistent with those from other clinical trials of β-amyloid-targeting monoclonal antibodies in patients with Alzheimer disease. Breakdown of the blood-brain barrier may result in increased drug entry into the central nervous system that could have important safety implications because adverse events are generally dose-dependent. They would be grateful if Dr Sims and colleagues could discuss any data or insights they may have on the possible role of higher CSF donanemab levels in the increased risk for amyloid-related imaging abnormalities associated with the APOE ε4 genotype.</description><subject>Abnormalities</subject><subject>Alzheimer's disease</subject><subject>Apolipoprotein E</subject><subject>Blood-brain barrier</subject><subject>Central nervous system</subject><subject>Cerebrospinal fluid</subject><subject>Clinical trials</subject><subject>Edema</subject><subject>Effusion</subject><subject>Genotypes</subject><subject>Medical imaging</subject><subject>Monoclonal antibodies</subject><subject>Neurodegenerative diseases</subject><subject>Neuroimaging</subject><subject>Risk factors</subject><subject>β-Amyloid</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNi7sOgjAYRhujiXiZXZs4A_1bLmUyRjTOXmZSTYmQXpDCgE8vgw_gt5zhnA-hDZAACIGwFloElFAWUACSTJAHMeM-izM-RR4hGffTiEdztHCuJuOApR7a3Z3EtsS5NcJILR64MvgoWjXg66CbzmrRVU-8V5-XrLRscV45KcZPiC-yUcMKzUqhnFz_uETb0_F2OPtNa9-9dF1R2741oypoBsASyhNg_1Vfy40-Ww</recordid><startdate>20231219</startdate><enddate>20231219</enddate><creator>Pomara, Nunzio</creator><creator>Imbimbo, Bruno Pietro</creator><creator>Evans, Cynthia D</creator><creator>Sims, John R</creator><general>American Medical Association</general><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20231219</creationdate><title>Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply</title><author>Pomara, Nunzio ; Imbimbo, Bruno Pietro ; Evans, Cynthia D ; Sims, John R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_29113628613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abnormalities</topic><topic>Alzheimer's disease</topic><topic>Apolipoprotein E</topic><topic>Blood-brain barrier</topic><topic>Central nervous system</topic><topic>Cerebrospinal fluid</topic><topic>Clinical trials</topic><topic>Edema</topic><topic>Effusion</topic><topic>Genotypes</topic><topic>Medical imaging</topic><topic>Monoclonal antibodies</topic><topic>Neurodegenerative diseases</topic><topic>Neuroimaging</topic><topic>Risk factors</topic><topic>β-Amyloid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pomara, Nunzio</creatorcontrib><creatorcontrib>Imbimbo, Bruno Pietro</creatorcontrib><creatorcontrib>Evans, Cynthia D</creatorcontrib><creatorcontrib>Sims, John R</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pomara, Nunzio</au><au>Imbimbo, Bruno Pietro</au><au>Evans, Cynthia D</au><au>Sims, John R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><date>2023-12-19</date><risdate>2023</risdate><volume>330</volume><issue>23</issue><spage>2304</spage><pages>2304-</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><abstract>Pomara and Imbimbo comment on the study on the use of donanemab in early symptomatic Alzheimer disease. The TRAILBLAZER-ALZ 2 trial 1 provided additional evidence that the APOE4 genotype is a risk factor for amyloid-related imaging abnormalities, especially cerebral edema and effusion. These findings are consistent with those from other clinical trials of β-amyloid-targeting monoclonal antibodies in patients with Alzheimer disease. Breakdown of the blood-brain barrier may result in increased drug entry into the central nervous system that could have important safety implications because adverse events are generally dose-dependent. They would be grateful if Dr Sims and colleagues could discuss any data or insights they may have on the possible role of higher CSF donanemab levels in the increased risk for amyloid-related imaging abnormalities associated with the APOE ε4 genotype.</abstract><cop>Chicago</cop><pub>American Medical Association</pub><doi>10.1001/jama.2023.21106</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2023-12, Vol.330 (23), p.2304 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_journals_2911362861 |
| source | American Medical Association Journals |
| subjects | Abnormalities Alzheimer's disease Apolipoprotein E Blood-brain barrier Central nervous system Cerebrospinal fluid Clinical trials Edema Effusion Genotypes Medical imaging Monoclonal antibodies Neurodegenerative diseases Neuroimaging Risk factors β-Amyloid |
| title | Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A32%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Donanemab%20in%20Early%20Symptomatic%20Alzheimer%20Disease%20/%20Reply&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Pomara,%20Nunzio&rft.date=2023-12-19&rft.volume=330&rft.issue=23&rft.spage=2304&rft.pages=2304-&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2023.21106&rft_dat=%3Cproquest%3E2911362861%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2911362861&rft_id=info:pmid/&rfr_iscdi=true |